Home
Search
Study Topics
Glossary
|
|
|
|
|
Sponsored by: |
Bayer |
---|---|
Information provided by: | Bayer |
ClinicalTrials.gov Identifier: | NCT00663806 |
Safety and efficacy of Cipro XR in a naturalistic setting and the effectiveness of an educational brochure. - Women with urinary tract infections were treated with Cipro XR. They were also given a brochure with information about urinary tract infections and later tested on the information.
Condition | Intervention | Phase |
---|---|---|
Urinary Tract Infections |
Behavioral: Cipro XR (Ciprofloxacin, BAYQ3939) |
Phase IV |
Study Type: | Interventional |
Study Design: | Randomized, Open Label, Uncontrolled, Parallel Assignment, Safety/Efficacy Study |
Official Title: | EXPRESS: Evaluating Cipro XR Patient Response, Education, Safety, and Satisfaction |
Enrollment: | 7614 |
Study Start Date: | February 2003 |
Study Completion Date: | July 2003 |
Arms | Assigned Interventions |
---|---|
Arm 1: Experimental |
Behavioral: Cipro XR (Ciprofloxacin, BAYQ3939)
Received Cipro XR (Ciprofloxacin, BAYQ3939) 500 mg once daily for 3 days and brochure about UTI
|
Arm 2: Experimental |
Behavioral: Cipro XR (Ciprofloxacin, BAYQ3939)
Received Cipro XR (Ciprofloxacin, BAYQ3939) 500 mg once daily for 3 days; not given brochure about UTI
|
Ages Eligible for Study: | 18 Years to 65 Years |
Genders Eligible for Study: | Female |
Accepts Healthy Volunteers: | No |
Inclusion Criteria:
Exclusion Criteria:
Responsible Party: | Medical Affairs Therapeutic Area Head ( Bayer Healthcare Pharmaceuticals Inc. ) |
Study ID Numbers: | 100534 |
Study First Received: | April 17, 2008 |
Last Updated: | March 4, 2009 |
ClinicalTrials.gov Identifier: | NCT00663806 History of Changes |
Health Authority: | United States: Institutional Review Board |
UTI |
Ciprofloxacin Urologic Diseases Urinary Tract Infections |
Anti-Infective Agents Ciprofloxacin Molecular Mechanisms of Pharmacological Action Urologic Diseases Therapeutic Uses |
Urinary Tract Infections Enzyme Inhibitors Infection Pharmacologic Actions Nucleic Acid Synthesis Inhibitors |